The US Food and Drug Administration has approved Rasonque (daraxonrasib), a new targeted treatment for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy or are not candidates for multiagent treatment. Taken once daily, the drug targets multiple forms of the RAS protein, a major driver of tumour growth in pancreatic cancer. In the 500-patient RASolute 302 trial, median overall survival reached 13.2 months with daraxonrasib compared with 6.7 months using standard chemotherapy. Median progression-free survival was 7.2 months versus 3.6 months, while 30% of patients experienced a measurable tumour response compared with 11% in the chemotherapy group. The results are particularly significant for a cancer that is often detected late and remains among the most difficult malignancies to treat. Rasonque is not a cure, however, and can cause important adverse effects including skin toxicity, diarrhoea, mouth inflammation and, more rarely, serious gastrointestinal and lung complications.
The approval follows several other advances that are gradually changing pancreatic cancer treatment. In 2024, the FDA approved the NALIRIFOX chemotherapy combination as a first-line option for metastatic pancreatic adenocarcinoma after a trial showed median survival of 11.1 months compared with 9.2 months for gemcitabine plus nab-paclitaxel. In February 2026, regulators approved Optune Pax, a portable device that delivers alternating electric fields designed to disrupt cancer-cell division. When added to chemotherapy for locally advanced pancreatic cancer, median survival increased from 14.2 to 16.2 months. Olaparib is another targeted option, although it applies only to a relatively small group of patients with inherited BRCA mutations. These treatments are not interchangeable, but together they illustrate a broader shift from relying almost entirely on conventional chemotherapy toward therapies selected according to the biology of each tumour.
Daraxonrasib may be especially important because RAS was considered an exceptionally difficult drug target for decades. Researchers are now studying whether similar approaches could work earlier in pancreatic cancer treatment and in other cancers driven by RAS alterations. For now, the most important conclusion is more measured: patients with previously treated metastatic pancreatic cancer have gained a new option that produced a substantial and statistically significant survival benefit in a randomised clinical trial. Sources: FDA, New England Journal of Medicine and the RASolute 302, NAPOLI-3 and PANOVA-3 trials.
